Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Drug Resistance

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    February 2022
  1. HUGUELEY B, Mcclung RP, Saduvala N, Oster AM, et al
    Baseline HIV drug resistance testing: 12 U.S. jurisdictions, 2014-2019.
    AIDS. 2022 Feb 9. pii: 00002030-900000000-96222.
    PubMed     Abstract available


  2. HERMANS LE, Hofstra LM, Schuurman R, Ter Heine R, et al
    HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment - week 96 results from the ITREMA trial.
    AIDS. 2022 Feb 1. pii: 00002030-900000000-96229.
    PubMed     Abstract available


    January 2022
  3. GENER AR
    Anticipating HIV drug resistance with appropriate sequencing methods.
    AIDS. 2022;36:147-148.
    PubMed    


    October 2021
  4. OLUNIYI PE, Ajogbasile FV, Zhou S, Fred-Akintunwa I, et al
    HIV-1 drug resistance and genetic diversity in a cohort of people living with HIV-1 in Nigeria.
    AIDS. 2021 Oct 7. pii: 00002030-900000000-96299.
    PubMed     Abstract available


  5. RONALD R, Gartland M, Li Z, Zhou N, et al
    Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
    AIDS. 2021 Oct 7. pii: 00002030-900000000-96298.
    PubMed     Abstract available


    July 2021
  6. MORAKA NO, Garcia-Broncano P, Hu Z, Ajibola G, et al
    Patterns of pre-treatment drug resistance mutations of very early diagnosed and treated infants in botswana.
    AIDS. 2021 Jul 28. pii: 00002030-900000000-96339.
    PubMed     Abstract available


    June 2021
  7. PENG AT, Huang SH, Sun HY, Huang YC, et al
    Use of dietary supplements containing polyvalent cations and antacids among people living with HIV and its impact on viral suppression.
    AIDS. 2021 Jun 1. pii: 00002030-900000000-96390.
    PubMed     Abstract available


    February 2021
  8. MCCLUSKEY SM, Kamelian K, Musinguzi N, Kigozi S, et al
    Pre-treatment integrase inhibitor resistance is uncommon in ART-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
    AIDS. 2021 Feb 23. pii: 00002030-900000000-96475.
    PubMed     Abstract available


  9. LI Y, Etemad B, Dele-Oni R, Sharaf R, et al
    Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
    AIDS. 2021 Feb 22. pii: 00002030-900000000-96478.
    PubMed     Abstract available


  10. ANDERSSON E, Ambikan A, Brannstrom J, Aralaguppe SG, et al
    High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden.
    AIDS. 2021;35:227-234.
    PubMed     Abstract available


    December 2020
  11. MONACO DC, Zapata L, Hunter E, Salomon H, et al
    Resistance profile of HIV-1 quasispecies in patients under treatment failure using single molecule, real-time sequencing.
    AIDS. 2020;34:2201-2210.
    PubMed     Abstract available


    November 2020
  12. MUCCINI C, Spagnuolo V, Canetti D, Bigoloni A, et al
    Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance.
    AIDS. 2020;34:2152-2155.
    PubMed    


    October 2020
  13. BAJEMA KL, Nance RM, Delaney JAC, Eaton E, et al
    Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017.
    AIDS. 2020 Oct 12. doi: 10.1097/QAD.0000000000002679.
    PubMed     Abstract available


  14. BENNETT SJ, Chunda-Liyoka C, Poppe LK, Meinders K, et al
    High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.
    AIDS. 2020;34:1833-1842.
    PubMed     Abstract available


    September 2020
  15. YOTSUMOTO M, Hachiya A, Ichiki A, Amano K, et al
    Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
    AIDS. 2020 Sep 14. doi: 10.1097/QAD.0000000000002688.
    PubMed    


    August 2020
  16. GAY CL, Neo DT, Devanathan AS, Kuruc JD, et al
    Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002652.
    PubMed     Abstract available


  17. INZAULE SC, Bertagnolio S, Kityo CM, Siwale M, et al
    The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
    AIDS. 2020;34:1559-1566.
    PubMed     Abstract available


    July 2020
  18. GIATSOU E, Abdi B, Plu I, Desire N, et al
    Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy.
    AIDS. 2020 Jul 21. doi: 10.1097/QAD.0000000000002616.
    PubMed     Abstract available


  19. INZAULE SC, Jordan MR, Cournil A, Giron-Callejas A, et al
    Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low- and middle-income countries.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002623.
    PubMed     Abstract available


    May 2020
  20. INZAULE SC, Jordan MR, Bello G, Wadonda-Kabondo N, et al
    High levels of resistance to nucleoside/nucleotide reverse transcriptase inhibitors in newly-diagnosed antiretroviral treatment naive children in sub-Saharan Africa.
    AIDS. 2020 May 20. doi: 10.1097/QAD.0000000000002580.
    PubMed     Abstract available


    March 2020
  21. PANPRADIST N, Beck IA, Ruth PS, Avila-Rios S, et al
    Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    AIDS. 2020 Mar 19. doi: 10.1097/QAD.0000000000002524.
    PubMed     Abstract available


  22. JAMES CW, Szabo S, Kahal D, Goldstein ND, et al
    The effect of multivitamins and polyvalent cations on virologic suppression with integrase strand transfer inhibitors.
    AIDS. 2020;34:487-489.
    PubMed    


    December 2019
  23. YE J, Hao M, Xing H, Zhang F, et al
    Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: A multicenter observational study.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002468.
    PubMed     Abstract available


  24. SALOU M, Butel C, Comlan AS, Konou AA, et al
    Challenges of scale-up to Dolutegravir based regimens in sub-Saharan Africa: a case study in Togo.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002470.
    PubMed     Abstract available


    November 2019
  25. MORANGUINHO I, Borrego P, Goncalves F, Gomes P, et al
    Genotypic resistance profiles of HIV-2 infected patients from Cape Verde failing first-line antiretroviral therapy.
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002431.
    PubMed     Abstract available


    October 2019
  26. FOGEL JM, Sivay MV, Cummings V, Wilson EA, et al
    HIV drug resistance in a cohort of HIV-infected men who have sex with men in the United States.
    AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002394.
    PubMed     Abstract available


  27. LIU L, Dai L, Yao J, Pan P, et al
    Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naive individuals in a tertiary care hospital in Beijing, China.
    AIDS. 2019;33:1945-1947.
    PubMed     Abstract available


    September 2019
  28. KOUAMOU V, Manasa J, Katzenstein D, McGregor AM, et al
    Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    AIDS. 2019;33:1729-1737.
    PubMed     Abstract available


    May 2019
  29. INZAULE SC, Mr J, Cournil A, Vitoria M, et al
    Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age: a double setback.
    AIDS. 2019 May 29. doi: 10.1097/QAD.0000000000002277.
    PubMed     Abstract available


  30. AMBROSIONI J, Rico JAF, Nicolas D, Mosquera MM, et al
    E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
    AIDS. 2019 May 6. doi: 10.1097/QAD.0000000000002243.
    PubMed     Abstract available


  31. MOYO S, Gaseitsiwe S, Zahralban-Steele M, Maruapula D, et al
    Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    AIDS. 2019;33:1073-1082.
    PubMed     Abstract available


  32. MILNE RS, Silverman RA, Beck IA, Mckernan-Mullin J, et al
    Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
    AIDS. 2019;33:941-951.
    PubMed     Abstract available


    April 2019
  33. ALESSANDRI-GRADT E, Unal G, Leoz M, Plantier JC, et al
    Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients.
    AIDS. 2019 Apr 3. doi: 10.1097/QAD.0000000000002215.
    PubMed     Abstract available


    December 2018
  34. TODESCO E, Wirden M, Calin R, Simon A, et al
    Caution is needed in interpreting HIV transmission chains by ultra-deep sequencing.
    AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002105.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: